Statera Biopharma, Inc.
STAB
$0.0001
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -12.79% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.79% | -22.95% | |||
| Cost of Revenue | -15.68% | -43.20% | |||
| Gross Profit | -11.76% | -11.84% | |||
| SG&A Expenses | -35.18% | -31.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.26% | -47.74% | |||
| Operating Income | 51.81% | 51.48% | |||
| Income Before Tax | 3.83% | 55.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.83% | 55.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 153.13% | 18.52% | |||
| Net Income | 3.97% | 55.04% | |||
| EBIT | 51.81% | 51.48% | |||
| EBITDA | 55.98% | 52.60% | |||
| EPS Basic | 4.99% | 65.38% | |||
| Normalized Basic EPS | 6.61% | 65.35% | |||
| EPS Diluted | 4.99% | 65.38% | |||
| Normalized Diluted EPS | 6.61% | 65.35% | |||
| Average Basic Shares Outstanding | 1.13% | 29.84% | |||
| Average Diluted Shares Outstanding | 1.13% | 29.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||